nsc 664704 has been researched along with Hearing Loss in 1 studies
kenpaullone: inhibits CDK1/cyclin B; structure in first source
kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).
Hearing Loss: A general term for the complete or partial loss of the ability to hear from one or both ears.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hazlitt, RA | 1 |
| Teitz, T | 1 |
| Bonga, JD | 1 |
| Fang, J | 1 |
| Diao, S | 1 |
| Iconaru, L | 1 |
| Yang, L | 1 |
| Goktug, AN | 1 |
| Currier, DG | 1 |
| Chen, T | 1 |
| Rankovic, Z | 1 |
| Min, J | 1 |
| Zuo, J | 1 |
1 other study available for nsc 664704 and Hearing Loss
| Article | Year |
|---|---|
Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss.
Topics: Animals; Antineoplastic Agents; Cisplatin; Cochlea; Cyclin-Dependent Kinase 2; Drug Evaluation, Prec | 2018 |